Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pozelimab Open-Label Extension in PNH
NCT04162470Phase 3Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Dec 2019
- Primary completion
- Apr 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of pozelimab in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Treatment-emergent Adverse Events at Week 104 and Lactate Dehydrogenase Response at Week 26. Started Dec 2019; status: terminated.
02
Drugs
pozelimab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT04162470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04162470.